Bibliographic Details
| Title: |
Does fasting plasma glucose values 5.1-5.6 mmol/l in the first trimester of gestation a matter? |
| Authors: |
Fahimeh Ramezani Tehrani, Farshad Farzadfar, Farhad Hosseinpanah, Maryam Rahmati, Faegheh Firouzi, Mehrandokht Abedini, Farzad Hadaegh, Majid Valizadeh, Farahnaz Torkestani, Davood Khalili, Masoud Solaymani-Dodaran, Razieh Bidhendi-Yarandi, Marzieh Bakhshandeh, Afshin Ostovar, Marzieh Rostami Dovom, Mina Amiri, Fereidoun Azizi, Samira Behboudi-Gandevani |
| Source: |
Frontiers in Endocrinology, Vol 14 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Diseases of the endocrine glands. Clinical endocrinology |
| Subject Terms: |
early screening, randomized non-inferiority field trial, gestational diabetes, first trimester of gestation, glucose values 5.1-5.6 mmol/l, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| More Details: |
ObjectivesThe aim of the study was to investigate the effect of treatment on pregnancy outcomes among women who had fasting plasma glucose (FPG) 5.1-5.6 mmol/l in the first trimester of pregnancy.MethodsWe performed a secondary-analysis of a randomized community non-inferiority trial of gestational diabetes mellitus (GDM) screening. All pregnant women with FPG values range 5.1-5.6 mmol/l in the first trimester of gestation were included in the present study (n=3297) and classified to either the (i) intervention group who received treatment for GDM along with usual prenatal care (n=1,198), (ii) control group who received usual-prenatal-care (n=2,099). Macrosomia/large for gestational age (LGA) and primary cesarean-section (C-S) were considered as primary-outcomes. A modified-Poisson-regression for binary outcome data with a log link function and robust error variance was used to RR (95%CI) for the associations between GDM status and incidence of pregnancy outcomes.ResultsThe mean maternal age and BMI of pregnant women in both study groups were similar. There were no statistically significant differences in the adjusted risks of adverse pregnancy outcomes, including macrosomia, primary C-S, preterm birth, hyperbilirubinemia, preeclampsia, NICU-admission, birth trauma, and LBW both groups.ConclusionsIt is found that treating women with first-trimester FPG values of 5.1-5.6 mmol/l could not improve adverse pregnancy outcomes including macrosomia, Primary C-S, Preterm birth, hypoglycemia, hypocalcemia, preeclampsia, NICU admission, Birth trauma and LBW. Therefore, extrapolating the FPG cut-off point of the second trimester to the first –which has been proposed by the IADPSG, might therefore not be appropriate.Clinical Trial Registrationhttps://www.irct.ir/trial/518, identifier IRCT138707081281N1. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1664-2392 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fendo.2023.1155007/full; https://doaj.org/toc/1664-2392 |
| DOI: |
10.3389/fendo.2023.1155007 |
| Access URL: |
https://doaj.org/article/edec4e758e634af4969f5c042e8fa4e1 |
| Accession Number: |
edsdoj.4e758e634af4969f5c042e8fa4e1 |
| Database: |
Directory of Open Access Journals |
